AstraZeneca plc (NYSE: AZN) and Daiichi Sankyo Company, Limited (TYO: 4568) announced that Enhertu (trastuzumab deruxtecan) has been approved by China’s National Medical Products Administration (NMPA) for a new indication: adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease following taxane‑ and trastuzumab‑based neoadjuvant treatment. Concurrently, a second conditionally approved indication in HER2‑positive early breast cancer — sequential to paclitaxel, trastuzumab, and pertuzumab (THP) for the neoadjuvant treatment of adult patients with HER2‑positive stage II (high‑risk) or stage III breast cancer — has been converted to full approval.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Product | Enhertu (trastuzumab deruxtecan) – HER2‑directed antibody‑drug conjugate (ADC) |
| New Indication Approved | Adjuvant treatment of adult patients with HER2‑positive early breast cancer with residual invasive disease after taxane‑ and trastuzumab‑based neoadjuvant treatment |
| Indication Converted to Full Approval | Sequential to paclitaxel, trastuzumab, and pertuzumab (THP) for neoadjuvant treatment of adult patients with HER2‑positive stage II (high‑risk) or stage III breast cancer |
| Prior Status of Neoadjuvant Indication | Conditional approval |
| Announcement Date | 8 Oct 2026 |
| Partnership | Jointly developed and commercialized by AstraZeneca and Daiichi Sankyo |
Drug Profile & Mechanism of Action
- Molecule: Trastuzumab deruxtecan, a HER2‑directed antibody‑drug conjugate (ADC).
- Structure: Composed of a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload — an exatecan derivative, DXd — via a cleavable tetrapeptide‑based linker.
- Technology Platform: Designed using Daiichi Sankyo’s proprietary DXd ADC technology, the engineering backbone of the company’s conjugate portfolio.
- Portfolio Position: The lead product in Daiichi Sankyo’s oncology portfolio and the most advanced project in AstraZeneca’s ADC platform.
- Mechanism Concept: Antibody‑mediated HER2 targeting delivers the membrane‑permeable topoisomerase I inhibitor into tumor cells, with the cleavable linker enabling payload release inside the cell and in the tumor microenvironment. (Class mechanism background; construct specifics as disclosed.)
Indication Context – HER2‑Positive Early Breast Cancer
- From Metastatic to Curative Intent: The two labels move trastuzumab deruxtecan into early breast cancer — the neoadjuvant (pre‑surgical) and adjuvant (post‑surgical) settings — where treatment goals are eradication of disease and prevention of recurrence rather than palliation.
- Neoadjuvant Positioning: The full approval covers use sequential to paclitaxel, trastuzumab, and pertuzumab (THP) in adult patients with stage II (high‑risk) or stage III HER2‑positive disease — the population for which intensive preoperative therapy is standard.
- Adjuvant Positioning: The new indication targets patients with residual invasive disease after taxane‑ and trastuzumab‑based neoadjuvant treatment — a subgroup widely recognized as carrying elevated recurrence risk and historically lacking intensified postoperative options.
- Continuum Coverage: Together, the approvals span the full perioperative continuum of higher‑stage HER2‑positive early breast cancer. Pivotal trial names and efficacy data underlying the approvals were not disclosed in the announcement.
Partnership & Commercial Framework
- Alliance History: Daiichi Sankyo and AstraZeneca entered into global collaborations in March 2019 and July 2020 to jointly develop and commercialize trastuzumab deruxtecan and datopotamab deruxtecan.
- Japan Rights: Daiichi Sankyo retains exclusive rights for each ADC product in Japan.
- Manufacturing & Supply: Daiichi Sankyo remains responsible for the manufacturing and supply of trastuzumab deruxtecan and datopotamab deruxtecan.
- Economics: Financial terms related to the China approvals were not disclosed.
Market Impact & Outlook
- Early‑Disease Expansion in China: The NMPA approvals extend Enhertu’s China label from advanced disease into HER2‑positive early breast cancer, a substantially larger patient population treated with curative intent.
- Regulatory De‑Risking: Conversion of the neoadjuvant indication from conditional to full approval completes the evidentiary requirements for that label and strengthens its standing with prescribers and payers.
- Alliance Value Creation: For both AstraZeneca and Daiichi Sankyo, the dual regulatory actions reinforce the commercial trajectory of the most advanced asset in their ADC collaboration.
- Competitive Landscape: Perioperative HER2‑targeted therapy is an intensifying arena; a full neoadjuvant label plus a new adjuvant indication positions trastuzumab deruxtecan across both sides of surgery. China pricing, reimbursement, and launch timing were not disclosed.
- Next Steps: Commercial rollout of the new and converted indications in China; any further filings in additional geographies or settings were not detailed in the announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Enhertu (trastuzumab deruxtecan), including its adjuvant and neoadjuvant use in HER2‑positive early breast cancer in China, commercial uptake, and the AstraZeneca–Daiichi Sankyo collaboration. Actual results may differ due to risks including reimbursement and pricing dynamics, real‑world safety experience, competitive entry, and further regulatory actions.-Fineline Info & Tech
